Clinical Trial Update: Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating dopamine transporter imaging with ioflupane (DaTscan) in Lewy body dementia and other dementias has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Lewy Body Dementia
• Vascular Dementia

Drugs mentioned

• DaTscan (ioflupane)

Snippet

Sponsor: GE Healthcare | Conditions: Lewy Body Dementia, Non-DLB Dementia | Phase 3 | Status: COMPLETED